Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Takashi, Sugisawa, Norihiko, Park, Jun Ho, Sun, Yu, Zhu, Guangwei, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356269/
https://www.ncbi.nlm.nih.gov/pubmed/32659740
http://dx.doi.org/10.1016/j.tranon.2020.100826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356269/
https://www.ncbi.nlm.nih.gov/pubmed/32659740
http://dx.doi.org/10.1016/j.tranon.2020.100826

Ejemplares similares